Genelux Corp. (GNLX), a clinical-stage immuno-oncology company, Friday announced that it has appointed Jason Litten as Chief Medical Officer, effective January 2.
Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones, the company said in a statement.
Litten is a veteran biopharmaceutical executive with over 20 years of experience spanning academia, pharmaceutical organizations, and biotech companies. Most recently he served as Chief Medical Officer at Chimeric Therapeutics, Ltd.
On Wednesday, GNLX shares closed at $4.36, up 0.46% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.